Other publications:

• Molloy E, Ramakrishnan S, Murphy E, Barry M. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. Rheumatology 2004; 43: 522-3.
• Molloy E, Cahill M, O?Hare JA. Cerebral venous sinus thrombosis precipitated by Graves? disease and factor V Leiden mutation. Ir Med J 2003; 96(2): 46-7.
• Molloy E, O?Hare JA. Unraveling medical outpatient referrals. Ir Med J 2003; 96(5): 145-6.
• Molloy E, Clarke D, Fearon U, Cunningham SK, McKenna TJ. Non-ACTH pro-opiomelanocortin fragments stimulate aldosterone production by human adrenal cells in vitro. Steroids 1998; 63(9): 459-463

Clinical Immunology Society

Cleveland Clinic physicians and scientists report if they have any collaborations with the pharmaceutical or medical device industries as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 11/3/2008, Dr. Molloy has reported no financial relationship with industry that is applicable to this listing. Patients should feel free to contact their doctor about relationships with industry and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

• English